Current PD-L1 immunohistochemistry for non-small cell lung cancer

Immunotherapy that targets PD-1 or PD-L1 by monoclonal antibodies has emerged as effective and safe new treatment of malignant tumours. It is most beneficial in highly immunogenic tumours, in particular in malignant melanoma (1) and in non-small cell lung cancer (NSCLC) (2). Immunohistochemistry (IHC) of PD-L1 protein may serve as predictive biomarker for both PD-1 and PD-L1 inhibitors.